INT87295

Context Info Confidence 0.60 First Reported 2000 Last Reported 2009 Negated 0 Speculated 0 Reported most in Abstract Documents 8 Total Number 8 Disease Relevance 7.99 Pain Relevance 2.00

Anatomy Link Frequency colon 2 ARMC3 (Homo sapiens)

Pain Link Frequency Relevance Heat aspirin 8 98.72 cINOD 22 97.04 COX-2 inhibitor 2 77.84 abdominal pain 1 72.68 COX2 2 25.00 cOX1 2 25.00

Disease Link Frequency Relevance Heat Apoptosis 27 99.00 Colon Cancer 38 98.96 Cancer 25 91.28 Recurrence 1 88.32 Metastasis 1 87.20 Rhinitis 1 86.36 INFLAMMATION 12 83.64 Urological Neuroanatomy 4 79.84 Renal Cancer 1 76.88 Abdominal Pain 1 72.68

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Inhibition of proteasome activity with MG-132 partially blocked the ability of sulindac sulfide and sulindac sulfone to inhibit beta-catenin protein expression.

Gene_expression (expression) of beta-catenin protein

1) Confidence 0.60 Published 2003 Journal Mol. Cancer Ther. Section Abstract Doc Link 14555707 Disease Relevance 0.91 Pain Relevance 0.14

Treatment of human colon cancer cell lines with apoptotic concentrations of sulindac metabolites (sulindac sulfide, sulindac sulfone) induced a dose- and time-dependent inhibition of beta-catenin protein expression.

Gene_expression (expression) of beta-catenin protein in colon associated with colon cancer and apoptosis

2) Confidence 0.60 Published 2003 Journal Mol. Cancer Ther. Section Abstract Doc Link 14555707 Disease Relevance 0.97 Pain Relevance 0.16

Pharmacologic activation of PKG with YC-1 increases JNK phosphorylation and induces apoptosis in colon cancer cells without modulating ERK1/2 phosphorylation or beta-catenin protein expression.

Gene_expression (expression) of beta-catenin protein in colon associated with colon cancer and apoptosis

3) Confidence 0.31 Published 2006 Journal Mol. Cancer Ther. Section Abstract Doc Link 16546990 Disease Relevance 1.13 Pain Relevance 0.13

Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.

Gene_expression (expression) of beta-catenin protein associated with apoptosis

4) Confidence 0.31 Published 2006 Journal Mol. Cancer Ther. Section Abstract Doc Link 16546990 Disease Relevance 0.98 Pain Relevance 0.16

Inhibition of ERK1/2 with U0126 induces apoptosis but fails to activate JNK phosphorylation or down-regulate beta-catenin protein expression.

Gene_expression (expression) of beta-catenin protein associated with apoptosis

5) Confidence 0.31 Published 2006 Journal Mol. Cancer Ther. Section Abstract Doc Link 16546990 Disease Relevance 1.12 Pain Relevance 0.12

Decreased beta-catenin protein expression may mediate the anti-proliferative effects of indomethacin.

Gene_expression (expression) of beta-catenin protein

6) Confidence 0.29 Published 2000 Journal Eur. J. Cancer Section Abstract Doc Link 10738133 Disease Relevance 0.68 Pain Relevance 0.59

Indomethacin decreased beta-catenin protein expression in all cells (unlike NS-398 or aspirin).

Gene_expression (expression) of beta-catenin protein associated with aspirin

7) Confidence 0.29 Published 2000 Journal Eur. J. Cancer Section Abstract Doc Link 10738133 Disease Relevance 0.71 Pain Relevance 0.62

They showed strong nuclear and cytoplasmic expression and reduced membranous expression of beta-catenin protein.

Gene_expression (expression) of beta-catenin protein

8) Confidence 0.01 Published 2009 Journal Malays J Pathol Section Abstract Doc Link 20514858 Disease Relevance 1.48 Pain Relevance 0.07

General Comments

This test has worked.